Nat Cell Biol, 2022, 24(10):1541-1557

Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells.

Glioblastoma (GBM) is characterized by exceptionally high intratumoral heterogeneity. However, the molecular mechanisms underlying the origin of different GBM cell populations remain unclear. Here, we found that the compositions of ribosomes of GBM cells in the tumour core and edge differ due to alternative RNA splicing. The acidic pH in the core switches before messenger RNA splicing of the ribosomal gene RPL22L1 towards the RPL22L1b isoform. This allows cells to survive acidosis, increases stemness and correlates with worse patient outcome. Mechanistically, RPL22L1b promotes RNA splicing by interacting with lncMALAT1 in the nucleus and inducing its degradation. Contrarily, in the tumour edge region, RPL22L1a interacts with ribosomes in the cytoplasm and upregulates the translation of multiple messenger RNAs including TP53. We found that the RPL22L1 isoform switch is regulated by SRSF4 and identified a compound that inhibits this process and decreases tumour growth. These findings demonstrate how distinct GBM cell populations arise during tumour growth. Targeting this mechanism may decrease GBM heterogeneity and facilitate therapy.

Larionova TD, Bastola S, Aksinina TE, Anufrieva KS, Wang J, Shender VO, Andreev DE, Kovalenko TF, Arapidi GP, Shnaider PV, Kazakova AN, Latyshev YA, Tatarskiy VV, Shtil AA, Moreau P, Giraud F, Li C, Wang Y, Rubtsova MP, Dontsova OA, Condro M, Ellingson BM, Shakhparonov MI, Kornblum HI, Nakano I, Pavlyukov MS

IBCH: 10234
Ссылка на статью в журнале: https://www.nature.com/articles/s41556-022-00994-w
Кол-во цитирований на 02.2024: 18
Данные статьи проверены модераторами 2022-10-15

Список научных проектов, где отмечена публикация

  1. 075-15-2020-773. . Сommercial.
  2. 075-15-2019-1669. . Сommercial.
  3. 22-15-00462. . Сommercial.
  4. 21-64-00006. . Сommercial.
  5. 19-34-90193. . Сommercial.
  6. - (January 13, 2020 — December 31, 2022). Pavliukov M.S.. Grant, RFBR.
  7. - (August 22, 2019 — December 31, 2021). Shahparonov M.I.. Grant, RFBR.
  8. MD-4501.2021.1.4. . Сommercial.
  9. SP-3815.2021.4. . Сommercial.
  10. 81802502. . Сommercial.
  11. P50CA211015. . Сommercial.
  12. R01CA241927. . Сommercial.
  13. R01CA270027. . Сommercial.
  14. R21CA223757. . Сommercial.
  15. R01CA201402. . Сommercial.
  16. R01NS121617. . Сommercial.
  17. R01NS107071. . Сommercial.
  18. R01NS113631. . Сommercial.
  19. RSG-15-003-01-CCE. . Сommercial.
  20. CA200290. . Сommercial.
  21. -Низкомолекулярные модуляторы сплайсинга РНК нового поколения как потенциальные препараты для терапии глиобластомы человека (January 6, 2022 — December 31, 2024). Shahparonov M.I.. Grant, RSF.